within Pharmacolibrary.Drugs.ATC.M;

model M04AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0025,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M04AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Allopurinol is a xanthine oxidase inhibitor used primarily to decrease high blood uric acid levels, commonly used in the management of chronic gout and to prevent uric acid nephropathy during cancer chemotherapy. It is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers (both male and female) after a single oral dose, fasted state.</p><h4>References</h4><ol><li><p>Toksvang, LN, et al., &amp; Schmiegelow, K (2022). Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. <i>Leukemia</i> 36(7) 1749–1758. DOI:<a href=\"https://doi.org/10.1038/s41375-022-01591-4\">10.1038/s41375-022-01591-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35654820/\">https://pubmed.ncbi.nlm.nih.gov/35654820</a></p></li><li><p>Murrell, GA, &amp; Rapeport, WG (1986). Clinical pharmacokinetics of allopurinol. <i>Clinical pharmacokinetics</i> 11(5) 343–353. DOI:<a href=\"https://doi.org/10.2165/00003088-198611050-00001\">10.2165/00003088-198611050-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3536254/\">https://pubmed.ncbi.nlm.nih.gov/3536254</a></p></li><li><p>Mills, PC, et al., &amp; Smith, NC (1995). The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. <i>Journal of veterinary pharmacology and therapeutics</i> 18(6) 451–456. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1995.tb00625.x\">10.1111/j.1365-2885.1995.tb00625.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8789699/\">https://pubmed.ncbi.nlm.nih.gov/8789699</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M04AA01;
